Abstract: The present disclosure provides compositions and methods comprising spherical nucleic acid (SNA) components for use as immunotherapeutic agents. The disclosure provides a method comprising: treating a population of antigen presenting cells with a SNA comprising a nanoparticle, an antigen, and an adjuvant; and determining a time at which the population of antigen presenting cells presents a maximal signal that is indicative of antigen presentation by the antigen presenting cells and a time at which the population of antigen presenting cells presents a maximal co-stimulatory signal due to the adjuvant. The disclosure includes compositions that comprise a pharmaceutically acceptable carrier and a SNA of the disclosure, wherein the SNA comprises a nanoparticle, an oligonucleotide on the surface of the nanoparticle, and an antigen that is associated with the surface of the SNA via a linker. The disclosure additionally includes articles of manufacture and kits.

Abstract: The disclosure is generally directed to immunostimulatory protein-core spherical nucleic acids (SNAs) comprising a protein core and a ratio of immunostimulatory and non-immunostimulatory strands, methods of making the immunostimulatory protein-core SNAs as well as their use.

Abstract: Disclosed herein are spherical nucleic acids (SNAs) comprising oligonucleotides comprising one or more modified oligonucleotides, and methods of use thereof. Also disclosed are methods of synthesizing modified oligonucleotides for use in therapeutics, including deoxynucleic guanidine (DNG)-modified oligonucleotides.

Abstract: The present disclosure provides compositions and methods comprising spherical nucleic acid (SNA) components for use as immunotherapeutic agents. The disclosure provides a method comprising: treating a population of antigen presenting cells with a SNA comprising a nanoparticle, an antigen, and an adjuvant; and determining a time at which the population of antigen presenting cells presents a maximal signal that is indicative of antigen presentation by the antigen presenting cells and a time at which the population of antigen presenting cells presents a maximal co-stimulatory signal due to the adjuvant. The disclosure includes compositions that comprise a pharmaceutically acceptable carrier and a SNA of the disclosure, wherein the SNA comprises a nanoparticle, an oligonucleotide on the surface of the nanoparticle, and an antigen that is associated with the surface of the SNA via a linker. The disclosure additionally includes articles of manufacture and kits.

Abstract: The present disclosure provides compositions and methods directed to combining spherical nucleic acid (SNA) components that are required for T-cell activation and proliferation.

Abstract: This disclosure is directed to methods of preparing organic aldehydes, each method comprising contacting a terminal olefin with an oxidizing mixture comprising: (a) a dichloro-palladium complex; (b) a copper complex; (c) a source of nitrite; under aerobic reaction conditions sufficient to convert at least a portion of the terminal olefin to an aldehyde.

Abstract: This disclosure is directed to methods of preparing organic aldehydes, each method comprising contacting a terminal olefin with an oxidizing mixture comprising: (a) a dichloro-palladium complex; (b) a copper complex; (c) a source of nitrite; under aerobic reaction conditions sufficient to convert at least a portion of the terminal olefin to an aldehyde.